Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy

Mizuho Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy with a price target of $50.00 (from $40.00).

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $40.25 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Aker Solutions ASA (AKSO:NO) (AKRTF) to Neutral
• Pernod Ricard SA (RI:FP) (PDRDY) PT Raised to EUR152 at Morgan Stanley
• Getlink (GET:FP) (GRPTF) PT Raised to EUR19.50 at Morgan Stanley